A case of severe side effects to androgen receptor inhibitor and consequently switch to radioligand therapy in early castration resistant prostate cancer

Andreas Tulipan; Clemens Kratochwil; Jacob Lilleby; Wolfgang Lilleby

doi:10.1016/j.eucr.2024.102752

A case of severe side effects to androgen receptor inhibitor and consequently switch to radioligand therapy in early castration resistant prostate cancer

Andreas Tulipan
, Clemens Kratochwil
, Jacob Lilleby
, Wolfgang Lilleby (Corresponding Author)

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

9 Downloads (Pure)

Abstract

The development of potent novel androgen receptor inhibitors (ARi) such as apalutamide have improved the life
expectancy in men with castration-resistant prostate cancer (CRPCa). However, some serious toxicity can occur
limiting the choice of treatment in CRPCa. In our case, the patient experienced severe toxicity after initiation of
apalutamide. Diagnostic PSMA-PET/CT confirmed the recurrence and tailored the treatment with 177Lu-PSMA617 (RLT), a beta emitter radionuclide. RLT resulted in prolonged progression-free survival, thus postponing the commonly seen additional toxicity of chemotherapy.
The case highlights the possibility of early RLT in PSMA avid tumors, a treatment with minimal side-effects.

Original language	English
Article number	102752
Pages (from-to)	1-3
Number of pages	3
Journal	Urology Case Reports
Volume	54
DOIs	https://doi.org/10.1016/j.eucr.2024.102752
Publication status	Published - May 2024
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords*

Androgen receptor inhibitor
Prostate cancer
Radioligand therapy

Field of Science*

3.2 Clinical medicine

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

Access to Document

10.1016/j.eucr.2024.102752Licence: CC BY

A case of severe side effects to androgen receptor inhibitorFinal published version, 1.65 MBLicence: CC BY

Cite this

@article{238ccfd94c07409580c9c1e2f141a277,

title = "A case of severe side effects to androgen receptor inhibitor and consequently switch to radioligand therapy in early castration resistant prostate cancer",

abstract = "The development of potent novel androgen receptor inhibitors (ARi) such as apalutamide have improved the life expectancy in men with castration-resistant prostate cancer (CRPCa). However, some serious toxicity can occur limiting the choice of treatment in CRPCa. In our case, the patient experienced severe toxicity after initiation of apalutamide. Diagnostic PSMA-PET/CT confirmed the recurrence and tailored the treatment with 177Lu-PSMA617 (RLT), a beta emitter radionuclide. RLT resulted in prolonged progression-free survival, thus postponing the commonly seen additional toxicity of chemotherapy. The case highlights the possibility of early RLT in PSMA avid tumors, a treatment with minimal side-effects.",

keywords = "Androgen receptor inhibitor, Prostate cancer, Radioligand therapy",

author = "Andreas Tulipan and Clemens Kratochwil and Jacob Lilleby and Wolfgang Lilleby",

year = "2024",

month = may,

doi = "10.1016/j.eucr.2024.102752",

language = "English",

volume = "54",

pages = "1--3",

journal = "Urology Case Reports",

issn = "2214-4420",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - A case of severe side effects to androgen receptor inhibitor and consequently switch to radioligand therapy in early castration resistant prostate cancer

AU - Tulipan, Andreas

AU - Kratochwil, Clemens

AU - Lilleby, Jacob

AU - Lilleby, Wolfgang

PY - 2024/5

Y1 - 2024/5

N2 - The development of potent novel androgen receptor inhibitors (ARi) such as apalutamide have improved the life expectancy in men with castration-resistant prostate cancer (CRPCa). However, some serious toxicity can occur limiting the choice of treatment in CRPCa. In our case, the patient experienced severe toxicity after initiation of apalutamide. Diagnostic PSMA-PET/CT confirmed the recurrence and tailored the treatment with 177Lu-PSMA617 (RLT), a beta emitter radionuclide. RLT resulted in prolonged progression-free survival, thus postponing the commonly seen additional toxicity of chemotherapy. The case highlights the possibility of early RLT in PSMA avid tumors, a treatment with minimal side-effects.

AB - The development of potent novel androgen receptor inhibitors (ARi) such as apalutamide have improved the life expectancy in men with castration-resistant prostate cancer (CRPCa). However, some serious toxicity can occur limiting the choice of treatment in CRPCa. In our case, the patient experienced severe toxicity after initiation of apalutamide. Diagnostic PSMA-PET/CT confirmed the recurrence and tailored the treatment with 177Lu-PSMA617 (RLT), a beta emitter radionuclide. RLT resulted in prolonged progression-free survival, thus postponing the commonly seen additional toxicity of chemotherapy. The case highlights the possibility of early RLT in PSMA avid tumors, a treatment with minimal side-effects.

KW - Androgen receptor inhibitor

KW - Prostate cancer

KW - Radioligand therapy

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=rsu_pure_&SrcAuth=WosAPI&KeyUT=WOS:001241824400001&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1016/j.eucr.2024.102752

DO - 10.1016/j.eucr.2024.102752

M3 - Article

C2 - 38779691

SN - 2214-4420

VL - 54

SP - 1

EP - 3

JO - Urology Case Reports

JF - Urology Case Reports

M1 - 102752

ER -

A case of severe side effects to androgen receptor inhibitor and consequently switch to radioligand therapy in early castration resistant prostate cancer

Abstract

UN SDGs

Keywords*

Field of Science*

Publication Type*

Access to Document

Other files and links

Fingerprint

Cite this